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Background
Flaxseed is one of the richest dietary sources of lignans, containing up to 0.05 -0.2% by weight of secoisolariciresinol-diglycoside (SDG) [1] [2] [3] [4] [5] [6] , a complex plant lignan first isolated from flaxseed in 1956 7 and a precursor of the intestinally derived mammalian lignans enterodiol and enterolactone [8] [9] [10] . Urinary and serum enterolactone concentrations appear to be a useful surrogate marker of fiber intake [11] [12] [13] .
We first showed that SDG is metabolized by intestinal bacteria in a series of steps that involve hydrolysis, dehydroxylation and demethylation to the intermediate enterodiol, and that this unique mammalian lignan is oxidized finally to enterolactone 9, 10, 14 . These observations were later confirmed by others 2, 4, 15 . Enterolactone and enterodiol were so named by Setchell & Kirk after the characteristics of their structures became evident, namely possession of γ-butyrolactone and butanediol structures, respectively 9, 16, 17 , and because physiologically both undergo enterohepatic recycling 1, 18 . The history of these discoveries was reviewed elsewhere 17 . There is a paucity of information on the pharmacokinetics and metabolism of SDG in humans [19] [20] [21] , although its metabolic fate and disposition has been reported in several animal studies [22] [23] [24] [25] .
Following the original discovery of enterolactone and enterodiol in urine 8, 26 and noting the close similarity in chemical structure to many plant derived lignans shown to have anticancer activity 1 , it was proposed that these novel mammalian lignans may be natural dietary anticancer agents 9 . Numerous studies have since shown an association between high lignan concentrations in urine or blood, and low rates of many chronic diseases, including cancers that are common to the Western world 27, 28 ; 29 30-39 . In contrast however, are a number of studies that fail to support associations between prostate, breast and esophageal cancers and lignans [40] [41] [42] [43] . Difficulties in elucidating the role of lignans in disease prevention is that most of these studies are epidemiological or have indirectly assessed lignan intake from diet recall or urinary and blood concentrations. Most have examined the role of flaxseed, a plant-based food that not only contains lignans but is also a rich source of n-3 fatty acids and fiber 44 , so that discerning the contribution of lignans in any proposed health 45, 46 effect can be difficult.
Dietary supplements of SDG extracts of flaxseed are now commercially available and fundamental knowledge of the pharmacokinetics, bioavailability and metabolism of SDG is crucial to designing clinical studies to examine the effectiveness of this natural plant lignan. We describe the metabolism and pharmacokinetics of SDG in healthy postmenopausal women, focusing on its bioavailability and intestinal metabolism to the mammalian lignans, enterodiol and enterolactone. We have examined a range of dietary intakes of SDG under single-bolus oral intake and after consecutive daily intakes, and finally we have determined whether extracts differing in purity alter the metabolism and pharmacokinetics of SDG.
Subjects and Methods
Preparation of the SDG supplement: Secoisolariciresinol diglycoside was isolated from flaxseeds by a propriatory process (Lignan Research Inc., San Diego, California). Several different extracts of SDG were used in these studies, differing in purity. Study 1 used an extract that was 43% pure SDG based on our HPLC and electrospray ionization mass spectrometric (ESI-MS) methods described below. Study 2 used a commercially available flaxseed extract that contained 28.8% SDG (Brevail TM , Lignan Research, San Diego, California), while Study 3 compared the pharmacokinetics of an extract of higher purity (74.4% pure SDG) with that of the 28.8% SDG commercial extract. These SDG extracts were prepared from commercially available flaxseeds and the amounts of SDG given were equivalent to that contained in 5 -17 g of whole flaxseeds. The doses of SDG were chosen based upon the estimated range of usual dietary intakes of this lignan from flaxseed, or from diets high in fiber-rich foods.
Study design
Three interrelated studies were carried out to determine the pharmacokinetics of SDG in healthy postmenopausal women, defined as being at least two years from the time of last menses. Study subjects were not taking hormone replacement therapy, antibiotics, diuretics or any 'over the counter' medications likely to affect, gastrointestinal, liver or kidney function. Anyone with evidence of preexisting chronic liver and gastrointestinal diseases, or who had been administered antibiotics within the 3 months prior to the study, or who were vegetarians were excluded.
Subjects were asked to abstain from eating flaxseed, or foods known to contain flaxseed for at least one week prior to, and during the studies. All blood samples collected from the 3 studies were centrifuged and the serum separated and immediately frozen at -20°C. The volumes of 12h urine pools were measured and 20 mL aliquots stored at -20°C until analyzed. Serum and urinary concentrations of secoisolariciresinol (SECO) and its principal metabolites, enterodiol and enterolactone were determined by GC-MS techniques developed in our laboratory and based on methodology reported previously 22, 47 .
Data analysis, sample-size and power calculations
Lignan pharmacokinetics were determined from the serum concentration (ng/mL) vs time profiles for SECO, enterodiol and enterolactone employing a non-compartmental approach using WinNonlin 4.1 (Pharsight Corporation, Cary, NC) computer software as described previously 48 .
Urinary lignan excretion was expressed as mg/day by combining the urinary outputs for the 12h collections, and cumulative excretion for each lignan was determined over 96h. The fraction of the lignan excreted in urine was determined as the ratio of the cumulative amount of the sum of SECO, enterodiol and enterolactone excreted to the administered dose of SDG adjusted for the differences in the molecular weights due to the glucose moieties. Dose adjusted data for Cmax and AUCinf were calculated relative to the amount of SDG ingested. These studies were of a 7 descriptive and observational nature. Power calculations were not performed to establish optimal sample-size because at the time of this study there was no prior published data on the pharmacokinetics of SDG to base calculations on. Rather, the sample-size was based on a compromise between what could feasibly be done in terms of the analytical load and having sufficient numbers of subjects to be able to observe dose-response effects. Comparison of the pharmacokinetic parameters among the different levels of SDG intakes was made using ANOVA and Students t-test.
Analytical methods
Determination of SDG content of flaxseed extracts by HPLC-ESI-MS analysis.
The content of secoisolariciresinol (SECO) was measured by HPLC with electrospray ionization-mass spectrometry ESI-MS after enzymatic hydrolysis of glycoside moieties of the SDG extracts.
Stable-isotopically labeled SECO, prepared by the late Professor DN Kirk, University of London by methodology described for stable-labeled enterolactone and enterodiol 16, 22 was used as an internal standard for quantification. Both SDG and SECO are detectable from their corresponding molecular ions thus providing a check on the completeness of enzymatic hydrolysis of the glycosides groups. Accurate amounts of each SDG sample extract were weighed, solubilized in distilled water, and the sample subjected to overnight hydrolysis by Helix pomatia digestive juice in buffer 6 . This enzyme was previously shown to have a high β-glucosidase activity toward isoflavones 49 and similarly hydrolyzes lignan glucosides efficiently.
The buffered enzyme solution was first prepared by mixing 50 mL of 0.5 M sodium acetate buffer, pH 4.5 and 1.0 mL of Helix pomatia digestive juice. This solution was passed through a C 18 Bond Elut solid-phase cartridge that had been pre-charged by washing with 5 mL methanol followed by 5 mL water. This purified enzyme solution was added (5 mL) to each sample and Analysis of Secoisolariciresinol, Enterodiol and Enterolactone in serum and urine by mass spectrometry. The concentrations of lignans in serum and urine (0.5 mL) were measured by stable-isotope dilution mass spectrometry with selected ion monitoring after addition of stableisotopically labeled internal standards for quantification 22 . The methodology followed essentially the same approach we have reported for the measurement of isoflavones 48, 49 . PA). The column was eluted with a gradient of water/acetonitrile. The initial mobile phase was 95% 10mmol/L ammonium acetate, 5% acetonitrile decreasing to 70% 10mmol/L ammonium acetate, 30% acetonitrile over the first 1 min. This was further decreased to 25% 10mmol/L ammonium acetate in a constant gradient from 1 to 16 min, and then finally held isocratic with 25% 10mmol/L ammonium acetate, 75% acetonitrile for 2 min before returning to the original composition of 95% 10mmol/L ammonium acetate, 5% acetonitrile. ESI-MS/MS was performed on a Micromass Quattro LC. The desolvation temperature was 375°C, and the source temperature was 100°C. The sample cone was held at 40 volts, and the extractor at 2 volts. A collision energy of 24 eV was used and the collision cell pressure was 2.8x10 -3 mbar. Data was collected in the negative ion mode. The lignan concentrations were established by comparing the lignan peak area ratio to that of the corresponding stable-labeled internal standards and interpolating these ratios against calibration plots constructed of known quantities of the pure lignans, secoisolariciresinol, enterodiol and enterolactone. The intra-assay precision of the method for serum lignans determined from replicate analysis of the same samples and expressed as coefficient of variation was 13%, 8%, and 16% for SECO, enterodiol and enterolactone, respectively. The intra-assay precision of the method for quantifying urinary lignans was 6%, 6%, and 7%, for SECO, enterodiol and enterolactone, respectively.
Results
Analysis of the Secoisolariciresinol-diglycoside extracts. When aliquots of the Stock solutions of the SDG extracts were analyzed directly, without enzymatic hydrolysis, LC-MS analysis revealed only a single peak eluting at 7.51 min corresponding to the protonated molecular ion (m/z 685) of SDG, and there was no detectable peak for SECO (m/z 361). By contrast, following enzymatic hydrolysis with Helix pomatia SDG was no longer present and the mass spectrometric analysis revealed exclusively a peak corresponding to SECO eluting at retention time 8.9 min (Fig. 1) . These studies established that under the enzymatic conditions employed, hydrolysis of SDG was complete. Using this approach the purity of the 3 different extracts of SDG used in the pharmacokinetic studies was determined to be 43% pure SDG, (Study 1), 28. Despite some inter-individual variation in serum concentrations there was a significant doseresponse effect (Table 1 ). The serum concentration profiles revealed a rapid absorption of SECO with average peak serum concentrations occurring 7.2 ± 1.0 h after ingestion of SDG (Table 1) , and elimination of SECO from serum was in accord with first-order kinetics. There was no significant difference in the time to reach peak serum SECO concentrations (t max ) between the two doses of SDG. The mean (±SEM) elimination half-life (t 1/2 ) for SECO was relatively rapid at 4.2 ± 0.3 h. The average volume of distribution (Vd/F) was high (111.5 ± 14.2 L), and the clearance rate rapid at 18.1 ± 1.7 L/h. The apparent bioavailability as measured from the AUC inf for serum SECO concentrations increased directly in proportion to the amount of SDG ingested and this was evident from the finding of no significant differences in the dose adjusted AUC inf and C max values (Table 1) .
With both doses of SDG, the appearance of enterodiol and enterolactone in serum was delayed relative to SECO which is consistent with production of these metabolites in the distal intestine and colon, and in accord with the known precursor-product relationship between these lignans (Fig. 2) . The average time to reach peak serum enterodiol and enterolactone concentrations was 19.2 ± 2.5 h and 26.7 ± 2. respectively. The mean elimination half-life of enterodiol and enterolactone was 9.0 and 11.6 h, respectively ( Table 1) .
The mean cumulative excretion of SECO, enterodiol and enterolactone over the 5 days that urine was collected shown in Fig. 3 . The urinary excretion profiles of these lignans were similar for both doses of SDG administered. SECO appeared in urine rapidly and reached almost maximal cumulative excretion within the first 24 h. Enterodiol appearance in urine was delayed with little appearing in the first 12 h after ingestion of SDG and near maximal cumulative excretion was attained after 48 h. The appearance of enterolactone in urine was still further delayed and even after 5-days complete excretion had not occurred, although it was estimated that about 90% cumulative excretion was attained by this time. Based on the amounts of SDG ingested, the mean % recovery of total lignans, the sum of SECO, enterodiol and enterolactone recovered in urine, was 74.6% and 68.2%, respectively for the two doses. Correlations between serum and urinary lignans. Since the single-oral bolus pharmacokinetics of SDG were similar in Studies 1 and 3 and lignan pharmacokinetics were unaffected by the relative purity of the extracts ingested, data were collectively analyzed to examine the relationship between serum and urinary lignans for all 20 women (Table 3) . Linear positive correlations were observed between the bioavailability of SECO (r 2 = 0.835), enterodiol (r 2 = 0.623) and enterolactone (r 2 = 0.634) and the cumulative 5-day urinary excretion of these lignans (Fig. 7) .
Discussion
The difficulty in interpreting nutritional and clinical studies of flaxseed is that flax contains many nutrients that could contribute to the reported biological effects 45, 46 . Studies of purified SDG extracts, which are now commercially available as supplements, provide one means of overcoming this limitation and of teasing out the potential importance of the lignan component of flaxseed. However, there have been few studies on the bioavailability or metabolic fate of SDG, or on the dynamics of its conversion to enterodiol and enterolactone in humans [19] [20] [21] . A number of studies have examined the effects of feeding flaxseeds to humans on urinary 19, [50] [51] [52] [53] and plasma 19, 54 enterodiol and enterolactone concentrations and there is a wealth of literature related to typical concentrations in people on habitual diets 13, [55] [56] [57] [58] [59] [60] [61] [62] [63] . Few have included measurements of SECO and there is only limited or incomplete information on the dynamics of SDG metabolism. One study described the metabolism of SDG in raw ground flaxseed fed to adults but blood collections were made for only 24 h after feeding 19 , an insufficient time for the accurate determination of the pharmacokinetics of enterodiol and enterolactone based on their delayed appearance in serum due to the fact that these lignans are produced by intestinal bacteria in the distal region of the intentianl tract 1, 17 . The only other pharmacokinetic study was a single dose study of SDG andministered to 12 healthy volunteers and only enterodiol and enterolactone was measured 20 . We have described the first multi-dosing study of the serum and urinary pharmacokinetics and metabolic fate of SDG in healthy postmenopausal women, focussing on dose-response effects and effects of using SDG extracts of flaxseed differing purity. These studies were performed using the classical single-bolus oral administration study design of serum appearance/disappearance kinetics of this lignan, and the dynamics of its hydrolysis to SECO and its rate of conversion to the specific metabolites enterodiol and enterolactone was also determined.
Data from Study 1 in which doses of 86 mg and 172 mg of SDG were administered as a single oral-bolus dose, when combined with the data from Study 3 of two different 50 mg doses yielded consistent dose-response information over a relatively wide range of dietary SDG intakes. The SDG extracts used in these studies differed in purity because of changes in the manufacturing processes employed over the course of these studies, but nevertheless our data show that irrespective of extract purity, the pharmacokinetics, bioavailability and metabolism of SDG is similar and not affected by the presence of other components in the flaxseed. Assessing the exact purity of SDG was difficult because of the lack of a highly pure synthetic standard of SDG for analytical calibration. Stable-isotope dilution analysis was therefore used to determine the actual purity of the SDG extracts administered, by determining the concentrations of the aglycon, SECO, released after enzymatic hydrolysis. Chemically synthesized SECO and its stable-labeled analog were used to quantify SECO, an approach that has been used in the compilation of several databases for the lignan content of foods 64, 65 . Enzymatic hydrolysis of whole and ground flaxseeds has previously been shown to yield lower values for the SDG content than if acid or alkaline hydrolysis is used and it has been suggested that enzymatic hydrolysis fails to completely hydrolyze SDG 5 . However, Helix pomatia digestive juice contains a high activity of β-glucosidase, and we have shown that it completely hydrolyzes glycosides of lignans (Figure 1) , and also isoflavones 49 . Hydrolysis efficiency can be readily monitored by ESI-MS 3, 66, 67 , because both SDG and SECO can be simultaneously detected with very high sensitivity by monitoring specific ions for these compounds. By this approach, under the enzymatic conditions employed, all SDG was converted to SECO and no SDG remained ( Figure   1 ). SECO has been shown to exist in oligomers 68 , and other chemical forms may exist within the seed that are resistant to enzymatic hydrolysis but could be released by more rigorous and destructive hydrolytic methods. This fraction of SDG would not be expected to be bioavailable since hydrolysis would not occur in the intestinal tract.
Following single-bolus oral administration of SDG, the appearance of SECO in serum was rapid with peak concentrations occurring after 5 -7 hours independent of the dose ingested or the extent of purity of the extract. This is reflective of rapid hydrolysis of the diglycoside moiety in the intestinal tract. The enzymes responsible for this hydrolytic cleavage of the sugar groups are presumed to reside on the brush border membrane of the proximal intestine and to be analogous to those involved in the hydrolysis of isoflavone glucosides 49, 69 . previously reported between enterolactone concentrations in serum and spot urines 60 . The fractional recovery of lignans in urine measured by the sum of SECO, enterodiol and enterolactone, ranged from 60 -80 %, which is significantly higher than reported for the fractional recovery of isoflavones from soy 48, 71, 72 . Assuming the approximate intake of SDG was 30 mg then the recovery of these lignans in feces, would have accounted for about 3 mg, or 10% of the ingested dose. Based on our pharmacokinetic studies it is apparent that renal clearance of isoflavones and elimination in the urine is the predominant route by which lignans are removed from the body.
Based on the pharmacokinetics displayed in these classical single-bolus oral administration studies it can be calculated that steady-state concentrations of lignans would be attained after 5-7 days of daily administration. This was confirmed in the data from Study 2 where the different doses of SDG (25, 50, 75 mg) were maintained for 8-consecutive days and serum measurements of SECO enterodiol and enterolactone made on days 7 and 8 ( Figure 4 ).
Although there was some inter-individual variation among the subjects within the dosing groups, there was no significant difference in the serum concentrations for any of the lignans between the two days and this was the case for all doses of SDG taken. These findings indicate steady-state had been attained after one week of intake of SDG, a conclusion similarly made after feeding ground flaxseed for 8 consecutive days 19, 51, 52 . Based on our pharmacokinetic data a dietary intake of 50 mg purified SDG would appear to provide similar urinary enterolactone excretion rates to those observed after feeding about 5-10 g flaxseed. Circulating enterolactone concentrations observed in our study for intakes of 50 mg of SDG are similar to those associated with reduced risk for breast cancer 73 and cardiovascular disease 27 .
Finally, our studies demonstrate that the pharmacokinetics and metabolism of SDG was not influenced by the presence of differing levels of impurities in the extracts. Many of these other components were characterized by the manufacturer to include caffeic, ferulic, cinnamic and coumaric acids, pinoresinol-diglycoside and other products of secondary plant metabolism.
Given that there is generally considerable variability in the purity of commercial dietary supplements of natural plant extracts, as has been previously shown for soy isoflavone supplements [74] [75] [76] , the issue of whether the these other components could alter the pharmacokinetics of the active ingredient is important to evaluate. Our studies show that the pharmacokinetic behavior and metabolism of SDG was similar over a range of extracts differing in SDG purity from 28.8% to 74.4%. This also indicates that, even if other secondary plant compounds are present, SDG is by far the major contributor to enterodiol and enterolactone production.
In conclusion, our studies define accurately the time-course for the dynamics of lignan formation from SDG and provide fundamental data on the pharmacokinetics of lignans in healthy adults. Such data will facilitate the design of future clinical studies aimed at evaluating the nutritional benefits of SDG, as opposed to flaxseeds, by utilizing purified SDG extracts. Summary of the serum pharmacokinetics of secoisolariciresinol, enterodiol and enterolactone for healthy postmenopausal women determined from lignan concentrations after single-bolus oral intake of 86 mg (n=5 women), and 172 mg (n=5 women) of a 43% pure secoisolariciresinol-diglycoside (SDG) extract. ¥= Dose-adjusted based on level of SDG intake * p ≤0.001, + p=0.05, # p ≤0.01 Cmax = peak serum concentration, Tmax = time required to reach peak levels, Vd/F = volume of distribition normalized to the bioavailable fraction, CL/F = systemic clearance normalized to bioavailabale fraction, AUCinf = bioavailablity as apparent from area under the curve to infinity, D = dose. Vd/F and Cl/F and AUCinf/D for enteriodiol and enterolactone not computed since dose of these lignans is unknown. C max /Dose SDG (ng/mL/mg) 5.2 ± 0.5 0.6 ± 0.07 0.5 ± 0.1 C max = peak serum concentration, Tmax = time required to reach peak levels, Vd/F = volume of distribution normalized to the bioavailable fraction, CL/F = systemic clearance normalized to bioavailable fraction, AUC inf = bioavailability as apparent from area under the curve to infinity. 
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